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evidence of the effect of postmastectomy radiotherapy 
on patient-reported outcomes and QOL.
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Follicular lymphoma is the most common subtype of 
indolent B-cell lymphoma, and patient outcomes are 
highly hetero geneous, with 20–30% of patients having 
aggressive (rather than indolent) disease.1 These high-
risk patients would benefit from a personalised approach 
to their care if validated and accurate prognostic tools 
were available to identify them as soon as possible after 
diagnosis. Although many prognostic tools and indices 
to predict survival in follicular lymphoma have been 
developed in the past 20 years, none of them have yet 
proven useful in therapeutic decision making.1 The many 
reasons explaining the gap between prognostic and 
therapeutic research in follicular lymphoma include the 
relatively low accuracy of published scores, with high 
frequency of false positives and negatives, their poor 
ability to predict overall survival, the time lag before 
relevant prognostic information is available (eg, the use 
of disease progression within 24 months as a prognostic 
indicator), technical difficulties in the index calculation, 
and the stability of the prognostic score or index under 
the conditions of different treatment regimens (eg, 
R-CHOP [rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisone or prednisolone], rituximab 
plus bendamustine, and R-CVP [rituximab plus cyclo-
phosphamide, vincristine, and prednisone]) or main-
tenance therapy with anti-CD20 monoclonal antibodies.
In The Lancet Oncology, Judith Trotman and 
colleagues2 describe the results of the largest 
study so far to investigate the prognostic role of 
metabolic response in more than 500 patients with 
previously untreated, advanced-stage follicular 
lymphoma who were enrolled in the randomised 
phase 3 GALLIUM trial.3 These investigators should 
be congratulated for the prospective inclusion of 
¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET among the 
required study procedures, and for the high quality 
of the central review process of metabolic response. 
Their findings showed that metabolic response to 
induction immunochemotherapy was prognostic for 
both progression-free and overall survival (eg, 2·5-year 
progression-free survival according to Lugano 2014 
criteria was 87·4% [95% CI 83·7–90·2] in complete 
metabolic responders vs 54·9% [40·5–67·3] in non-
complete metabolic responders; hazard ratio [HR] 0·2, 
95% CI 0·1–0·3, p<0·0001), and that Lugano response 
criteria were accurate and reproducible in follicular 
lymphoma. Furthermore, the investigators suggest 
that FDG-PET is the only diagnostic test required to 
assess response. More importantly, the results of the 
study show it is possible to generalise the prognostic 
role of metabolic response to nearly all patients with 
advanced-stage follicular lymphoma, including those 
receiving maintenance therapy and those treated with 
the new-generation anti-CD20 monoclonal antibody 
obinutuzumab. Lastly, although the study was not 
powered to analyse survival differences between 
different chemotherapy regimens, the stability of 
metabolic response with different treatments was 
strongly supported by the similar efficacy results with 
different treatment regimens. Therefore, because 
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metabolic response in follicular lymphoma fulfils 
most of the required criteria of an accurate prognostic 
test, it seems to be the best candidate among 
prognostic features to develop risk-adapted therapies 
in this disease. Indeed, clinical trials are underway that 
investigate the efficacy of a response-adapted approach 
based on the use of FDG-PET (eg, NCT02063685 and 
EudraCT 2016-004010-10).
Nevertheless, some additional considerations are 
needed to better guide future steps towards a personalised 
approach to follicular lymphoma care. First, Trotman 
and colleagues suggest that with the most active 
immunochemotherapy available today, the prognostic 
impact of metabolic response is confirmed. Its impact 
in clinical practice, however, is only available at the end 
of induction therapy and diminishes to approximately 
one out of ten patients with the use of a more potent 
antibody (ie, metabolic response was 18% in a previous 
prospective study with R-CHOP).4 Of the two methods 
used in the Trotman and colleagues’ study to analyse the 
prognostic role of metabolic response, the intention-
to-treat analysis overestimated the actual proportion 
of patients with metabolic response because it also 
included patients without post-induction FDG-PET 
among non-respon ders. Thus, the 450 (89%) patients 
with metabolic response among the 508 who qualified 
for the landmark analysis better describes the actual 
proportion of patients who are suitable for a response-
adapted approach. Second, the biological basis of 
a partial metabolic response is still not completely 
understood, and the major drivers of the increased 
risk of death in these high-risk patients remains 
unknown. Well-designed studies should try to clarify 
the association between absence of metabolic response 
and the risk of transformation or the presence of 
unfavourable pathological subtypes. Third, unlike in 
Hodgkin’s lymphoma or aggressive lymphomas, the 
timing of response assessment in follicular lymphoma 
has never been questioned; the possibility of identifying 
non-responders with response assessment at different 
timepoints thus remains unexplored. Finally, an 
urgent need remains for more active drugs in follicular 
lymphoma that could be moved from late to early 
treatment lines rapidly and safely and that could be 
incorporated into personalised, risk-adapted therapy to 
solve the problem of unfavourable outcomes in high-
risk patients.
In conclusion, a plateau in the curability of follicular 
lymphoma has probably been achieved thanks to highly 
active available immunochemotherapy regimens, but 
a proportion of patients still have high-risk features. 
Trotman and colleagues’ findings support metabolic 
response as one of the most important predictors of 
patient outcome, but its clinical significance is limited 
by the very low proportion of non-responding patients. 
The next generation of clinical trials in follicular 
lymphoma should be designed to test the efficacy of 
risk-adapted therapies in which metabolic response is 
integrated with robust clinical and biological prognostic 
factors to optimise the efficacy-to-safety ratio of therapy 
in the individual patient.
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